NASDAQ:RXDX - Ignyta Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$26.95 0.00 (0.00 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$26.95
Today's Range$26.95 - $26.95
52-Week Range$5.80 - $27.10
Volume254,655 shs
Average Volume3.04 million shs
Market Capitalization$1.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta184.87

About Ignyta (NASDAQ:RXDX)

Ignyta logoIgnyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Receive RXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:RXDX
CUSIPN/A
Phone+1-858-2555959

Debt

Debt-to-Equity Ratio0.34
Current Ratio6.07
Quick Ratio6.07

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.28 per share
Price / Book11.82

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-103,630,000.00
Net MarginsN/A
Return on Equity-113.09%
Return on Assets-68.72%

Miscellaneous

Employees112
Outstanding Shares67,590,000

Ignyta (NASDAQ:RXDX) Frequently Asked Questions

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

How were Ignyta's earnings last quarter?

Ignyta Inc (NASDAQ:RXDX) released its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.54) by $0.03. View Ignyta's Earnings History.

What price target have analysts set for RXDX?

5 brokerages have issued 1-year price targets for Ignyta's shares. Their forecasts range from $20.00 to $31.00. On average, they expect Ignyta's share price to reach $26.40 in the next twelve months. View Analyst Ratings for Ignyta.

What are Wall Street analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:
  • 1. Cantor Fitzgerald analysts commented, "The merger was announced on December 22, 2017, and the transaction was completed on February 8, 2018." (2/9/2018)
  • 2. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (1/17/2018)

Who are Ignyta's key executives?

Ignyta's management team includes the folowing people:
  • Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder (Age 45)
  • Jacob M. Chacko M.D., Chief Financial Officer (Age 38)
  • Zachary Hornby, Chief Operating Officer (Age 38)
  • Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls (Age 57)
  • Christian V. Kuhlen M.D. Esq., General Counsel, Secretary (Age 44)
  • William R. McCarthy, Chief Business Officer (Age 45)
  • Pratik S. Multani M.D., Chief Medical Officer (Age 50)
  • James A. Bristol Ph.D., Independent Director (Age 70)
  • Alexander W. Casdin, Independent Director (Age 49)
  • Heinrich Dreismann Ph.D., Independent Director (Age 64)

Has Ignyta been receiving favorable news coverage?

News stories about RXDX stock have been trending somewhat positive on Tuesday, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ignyta earned a coverage optimism score of 0.03 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 48.37 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Ignyta?

Shares of RXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ignyta's stock price today?

One share of RXDX stock can currently be purchased for approximately $26.95.

How big of a company is Ignyta?

Ignyta has a market capitalization of $1.79 billion. Ignyta employs 112 workers across the globe.

How can I contact Ignyta?

Ignyta's mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via phone at +1-858-2555959.


MarketBeat Community Rating for Ignyta (RXDX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe RXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ignyta (NASDAQ:RXDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Ignyta in the last 12 months. Their average twelve-month price target is $26.40, suggesting that the stock has a possible downside of 2.04%. The high price target for RXDX is $31.00 and the low price target for RXDX is $20.00. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.202.202.203.00
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.40$26.40$26.40$25.25
Price Target Upside: 2.04% downside2.15% downside2.15% downside69.46% upside

Ignyta (NASDAQ:RXDX) Consensus Price Target History

Price Target History for Ignyta (NASDAQ:RXDX)

Ignyta (NASDAQ:RXDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018Cantor FitzgeraldReiterated RatingHold$27.00LowView Rating Details
12/28/2017Jefferies GroupDowngradeBuy ➝ Hold$27.00LowView Rating Details
12/26/2017SunTrust BanksDowngradeBuy ➝ Hold$25.00 ➝ $27.00LowView Rating Details
12/26/2017Ladenburg ThalmannDowngradeBuy ➝ NeutralLowView Rating Details
10/12/2017JPMorgan ChaseReiterated RatingBuy$18.00 ➝ $20.00N/AView Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 ➝ $20.00N/AView Rating Details
7/12/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Ignyta (NASDAQ:RXDX) Earnings History and Estimates Chart

Earnings by Quarter for Ignyta (NASDAQ:RXDX)

Ignyta (NASDAQ:RXDX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.44)($0.44)($0.44)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.46)($0.46)($0.46)
Q4 20181($0.47)($0.47)($0.47)

Ignyta (NASDAQ RXDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.5370)($0.51)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.6280)($0.56)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.6870)($0.96)ViewN/AView Earnings Details
3/14/2017Q4 2016($0.67)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.67)($0.56)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.65)($0.68)ViewN/AView Earnings Details
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details
8/12/2014($0.26)($0.28)$0.15 millionViewN/AView Earnings Details
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ignyta (NASDAQ:RXDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ignyta (NASDAQ RXDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.08%
Institutional Ownership Percentage: 72.28%
Insider Trading History for Ignyta (NASDAQ:RXDX)
Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Ignyta (NASDAQ RXDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2016James A BristolDirectorBuy5,000$5.65$28,250.0021,667View SEC Filing  
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00100,000View SEC Filing  
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.0042,838View SEC Filing  
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.003,000View SEC Filing  
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.5297,000View SEC Filing  
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.006,438View SEC Filing  
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.003,325,148View SEC Filing  
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ignyta (NASDAQ RXDX) News Headlines

Source:
DateHeadline
Ignyta Inc (RXDX) Given Average Recommendation of "Hold" by AnalystsIgnyta Inc (RXDX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 30 at 9:46 AM
Ignyta (RXDX) Given a $15.00 Price Target at Cantor FitzgeraldIgnyta (RXDX) Given a $15.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 19 at 11:46 AM
Analyzing Roche’s Acquisition of Flatiron HealthAnalyzing Roche’s Acquisition of Flatiron Health
finance.yahoo.com - April 9 at 4:34 PM
Ignyta Inc (RXDX) Receives Average Recommendation of "Hold" from AnalystsIgnyta Inc (RXDX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 5 at 11:15 AM
Ignyta (RXDX) versus Kite Pharma (KITE) Critical ContrastIgnyta (RXDX) versus Kite Pharma (KITE) Critical Contrast
www.americanbankingnews.com - March 29 at 5:26 PM
Zacks Investment Research Upgrades Ignyta (RXDX) to "Buy"Zacks Investment Research Upgrades Ignyta (RXDX) to "Buy"
www.americanbankingnews.com - March 29 at 1:24 PM
Head-To-Head Comparison: Bioverativ (BIVV) and Ignyta (RXDX)Head-To-Head Comparison: Bioverativ (BIVV) and Ignyta (RXDX)
www.americanbankingnews.com - March 25 at 9:04 PM
Comparing Ignyta (RXDX) and Kite Pharma (KITE)Comparing Ignyta (RXDX) and Kite Pharma (KITE)
www.americanbankingnews.com - March 22 at 7:28 PM
Neuroderm (NDRM) vs. Ignyta (RXDX) Financial AnalysisNeuroderm (NDRM) vs. Ignyta (RXDX) Financial Analysis
www.americanbankingnews.com - March 18 at 3:12 PM
Ignyta Inc (RXDX) Given Average Rating of "Hold" by AnalystsIgnyta Inc (RXDX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 11 at 10:44 AM
Prosight Management LP Acquires New Stake in Ignyta Inc (RXDX)Prosight Management LP Acquires New Stake in Ignyta Inc (RXDX)
www.americanbankingnews.com - March 5 at 2:55 PM
Water Island Capital LLC Purchases Shares of 540,000 Ignyta Inc (RXDX)Water Island Capital LLC Purchases Shares of 540,000 Ignyta Inc (RXDX)
www.americanbankingnews.com - March 2 at 9:38 PM
Broadfin Capital LLC Sells 344,283 Shares of Ignyta Inc (RXDX)Broadfin Capital LLC Sells 344,283 Shares of Ignyta Inc (RXDX)
www.americanbankingnews.com - March 2 at 5:08 AM
Bogle Investment Management L P DE Sells 93,759 Shares of Ignyta Inc (RXDX)Bogle Investment Management L P DE Sells 93,759 Shares of Ignyta Inc (RXDX)
www.americanbankingnews.com - March 2 at 5:06 AM
Spark Investment Management LLC Buys 48,100 Shares of Ignyta Inc (RXDX)Spark Investment Management LLC Buys 48,100 Shares of Ignyta Inc (RXDX)
www.americanbankingnews.com - March 1 at 6:50 PM
Ignyta Inc (RXDX) Stake Increased by State of Wisconsin Investment BoardIgnyta Inc (RXDX) Stake Increased by State of Wisconsin Investment Board
www.americanbankingnews.com - March 1 at 6:10 PM
1,000,000 Shares in Ignyta Inc (RXDX) Acquired by Sand Grove Capital Management LLP1,000,000 Shares in Ignyta Inc (RXDX) Acquired by Sand Grove Capital Management LLP
www.americanbankingnews.com - March 1 at 4:45 PM
80,000 Shares in Ignyta Inc (RXDX) Purchased by Ontario Teachers Pension Plan Board80,000 Shares in Ignyta Inc (RXDX) Purchased by Ontario Teachers Pension Plan Board
www.americanbankingnews.com - February 26 at 12:28 PM
Carillon Tower Advisers Inc. Purchases Shares of 1,564,814 Ignyta Inc (RXDX)Carillon Tower Advisers Inc. Purchases Shares of 1,564,814 Ignyta Inc (RXDX)
www.americanbankingnews.com - February 26 at 12:18 PM
Ignyta Inc (RXDX) Receives Average Recommendation of "Hold" from BrokeragesIgnyta Inc (RXDX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 14 at 12:00 PM
Bonti Appoints Dr. Jacob Chacko to Board of DirectorsBonti Appoints Dr. Jacob Chacko to Board of Directors
www.bizjournals.com - February 12 at 9:12 AM
Cantor Fitzgerald Analysts Give Ignyta (RXDX) a $27.00 Price TargetCantor Fitzgerald Analysts Give Ignyta (RXDX) a $27.00 Price Target
www.americanbankingnews.com - February 9 at 7:16 PM
Ignyta (RXDX) Lifted to "Hold" at ValuEngineIgnyta (RXDX) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - February 4 at 2:52 PM
 Brokerages Expect Ignyta Inc (RXDX) to Announce -$0.44 EPS Brokerages Expect Ignyta Inc (RXDX) to Announce -$0.44 EPS
www.americanbankingnews.com - February 2 at 7:08 PM
Ignyta Inc (RXDX) Given Consensus Recommendation of "Hold" by BrokeragesIgnyta Inc (RXDX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 20 at 10:06 AM
Ignyta (RXDX) Lowered to "Hold" at Zacks Investment ResearchIgnyta (RXDX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 17 at 12:42 PM
 Analysts Expect Ignyta Inc (RXDX) Will Announce Earnings of -$0.44 Per Share Analysts Expect Ignyta Inc (RXDX) Will Announce Earnings of -$0.44 Per Share
www.americanbankingnews.com - January 16 at 7:56 PM
ACT NOW: Monteverde & Associates PC Announces An Investigation of Ignyta, Inc. - RXDXACT NOW: Monteverde & Associates PC Announces An Investigation of Ignyta, Inc. - RXDX
finance.yahoo.com - January 16 at 10:45 AM
Short Interest in Ignyta Inc (RXDX) Declines By 48.0%Short Interest in Ignyta Inc (RXDX) Declines By 48.0%
www.americanbankingnews.com - January 13 at 3:48 AM
Ignyta (RXDX) Stock Rating Lowered by Zacks Investment ResearchIgnyta (RXDX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 9 at 11:58 AM
Pre-Market Technical Scan on Biotech Equities -- Ignyta, Pluristem Therapeutics, Ritter Pharma, and Tenax Therapeutics - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Ignyta, Pluristem Therapeutics, Ritter Pharma, and Tenax Therapeutics - PR Newswire (press release)
www.prnewswire.com - January 8 at 11:00 AM
Ignyta to Present at 36th Annual J.P. Morgan Healthcare ConferenceIgnyta to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:59 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to Shareholders
finance.yahoo.com - January 3 at 3:29 PM
 Analysts Anticipate Ignyta Inc (RXDX) to Post -$0.44 EPS Analysts Anticipate Ignyta Inc (RXDX) to Post -$0.44 EPS
www.americanbankingnews.com - December 31 at 1:30 AM
Ignyta (RXDX) Downgraded by Jefferies Group to "Hold"Ignyta (RXDX) Downgraded by Jefferies Group to "Hold"
www.americanbankingnews.com - December 29 at 3:34 PM
Cantor Fitzgerald Reiterates $23.00 Price Target for Ignyta (RXDX)Cantor Fitzgerald Reiterates $23.00 Price Target for Ignyta (RXDX)
www.americanbankingnews.com - December 29 at 3:34 PM
Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM ... - Business Wire (press release)Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM ... - Business Wire (press release)
www.businesswire.com - December 29 at 3:29 PM
BRIEF-Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018BRIEF-Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018
www.reuters.com - December 29 at 10:58 AM
Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) InhibitorIgnyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
finance.yahoo.com - December 29 at 10:58 AM
Cantor Fitzgerald Downgrades Ignyta, Inc (RXDX) to Neutral Following AcquisitionCantor Fitzgerald Downgrades Ignyta, Inc (RXDX) to Neutral Following Acquisition
www.streetinsider.com - December 28 at 3:04 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to Shareholders
finance.yahoo.com - December 28 at 3:04 PM
Stock Traders Buy High Volume of Put Options on Ignyta (RXDX)Stock Traders Buy High Volume of Put Options on Ignyta (RXDX)
www.americanbankingnews.com - December 28 at 2:38 AM
Ignyta (RXDX) Lowered to Hold at Cantor FitzgeraldIgnyta (RXDX) Lowered to Hold at Cantor Fitzgerald
www.americanbankingnews.com - December 27 at 7:26 PM
Earnings Visibility Make Ignyta (RXDX) a Buy - Investorplace.comEarnings Visibility Make Ignyta (RXDX) a Buy - Investorplace.com
investorplace.com - December 27 at 6:35 PM
Ignyta (RXDX) and Its Peers Critical ContrastIgnyta (RXDX) and Its Peers Critical Contrast
www.americanbankingnews.com - December 26 at 9:21 PM
Analyzing Ignyta (RXDX) & Its CompetitorsAnalyzing Ignyta (RXDX) & Its Competitors
www.americanbankingnews.com - December 26 at 9:21 PM
Earnings Visibility Make Ignyta (RXDX) a BuyEarnings Visibility Make Ignyta (RXDX) a Buy
investorplace.com - December 26 at 11:17 AM
SunTrust Banks Lowers Ignyta (RXDX) to HoldSunTrust Banks Lowers Ignyta (RXDX) to Hold
www.americanbankingnews.com - December 26 at 10:38 AM
Ignyta (RXDX) Lowered to Neutral at Ladenburg Thalmann Financial ServicesIgnyta (RXDX) Lowered to Neutral at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - December 26 at 7:36 AM
WeissLaw LLP Investigates Ignyta Inc. Acquisition - PR Newswire (press release)WeissLaw LLP Investigates Ignyta Inc. Acquisition - PR Newswire (press release)
www.prnewswire.com - December 24 at 3:50 PM

SEC Filings

Ignyta (NASDAQ:RXDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ignyta (NASDAQ:RXDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ignyta (NASDAQ RXDX) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.